Literature DB >> 12626031

The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS.

G Uncu1, M C Sözer, O Develioğlu, C Cengiz.   

Abstract

All the components of the renin-angiotensin system have been identified in the human ovary. Renin plays a major role in folliculogenesis, and possibly in follicular atresia. Polycystic ovary syndrome (PCOS) is characterized by early follicular atresia. We studied whether assessment of plasma renin activity would be useful for diagnosing PCOS and distinguishing PCOS and non-PCOS in oligomenorrheic patients. Patients were divided into three groups: PCOS group (group 1, n = 40), non-PCOS oligomenorrheic group (group 2, n = 30) and ovulatory control group (group 3, n = 30). Plasma renin activity was determined in the early follicular phase of the menstrual cycle. Baseline serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin, insulin, aldosterone and androgens (total testosterone, free testosterone, androstenedione, dehydroepiandrosterone sulfate and 17alpha hydroxyprogesterone) were determined in all groups. The mean LH level was lower (4.94 +/- 4.65 mIU/ml) in control patients than in PCOS patients (12.9 +/- 1.75 mIU/ml) and non-PCOS oligomenorrheic patients (10.8 +/- 1.65 mIU/ml). There was no statistically significant difference between the groups regarding FSH levels. The mean plasma renin activity was 3.47 +/- 0.29 ng/ml in the PCOS group. The mean plasma renin activity was 1.59 +/- 0.21 ng/ml the non-PCOS oligomenorrheic group (statistically significiant differrence). There was no statistically significant difference between the non-PCOS oligomenorrheic (1.59 +/- 0.21 ng/ml) and control groups (1.2 +/- 0.16 ng/ml). Use of plasma renin activity alone as a diagnostic marker in PCOS is not useful, because the clinical findings of PCOS are heterogeneous and the pathogenesis is unclear. However, it can be used together with other variables to diagnose women with PCOS and to distinguish non-PCOS oligomenorrheic women from those with PCOS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12626031

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  3 in total

Review 1.  Polycystic Ovary Syndrome: Insights from Preclinical Research.

Authors:  Jane F Reckelhoff; Noha M Shawky; Damian G Romero; Licy L Yanes Cardozo
Journal:  Kidney360       Date:  2022-06-17

2.  Pregnancy Protects Hyperandrogenemic Female Rats From Postmenopausal Hypertension.

Authors:  Noha M Shawky; Chetan N Patil; Carolina Dalmasso; Rodrigo O Maranon; Damian G Romero; Heather Drummond; Jane F Reckelhoff
Journal:  Hypertension       Date:  2020-08-03       Impact factor: 10.190

3.  Systematic Evaluation of Genetic Variants for Polycystic Ovary Syndrome in a Chinese Population.

Authors:  Yuping Xu; Zhiqiang Li; Fenglian Ai; Jianhua Chen; Qiong Xing; Ping Zhou; Zhaolian Wei; Yongyong Shi; Xiao-Jin He; Yunxia Cao
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.